Form 4: PTC Therapeutics Director Receives Equity Grants

PTC Therapeutics Director Jessica Caroline Chutter was granted restricted stock units and stock options as part of her compensation.

Summary

• Director Jessica Caroline Chutter acquired 7,333 restricted stock units (RSUs) and stock options for 6,371 shares of common stock.
• The RSUs were granted on March 24, 2026, with 4,000 units vesting in three equal annual installments starting March 24, 2027.
• An additional 3,333 RSUs granted on March 24, 2026, will vest 1,000 shares on June 2, 2026, and 2,333 shares on January 2, 2027.
• Stock options for 3,475 shares were granted on March 24, 2026, with an exercise price of $64.54, vesting over 36 equal monthly installments starting April 24, 2026, and expiring March 23, 2036.
• Stock options for 2,896 shares were granted on March 24, 2026, with an exercise price of $64.54, vesting over 10 equal monthly installments starting April 2, 2026, and expiring March 23, 2036.
• All transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting standard director compensation practices that align management interests with shareholder value, without indicating any immediate operational changes or financial distress.

Positives

• Director Jessica Caroline Chutter received significant equity compensation, aligning her interests with shareholders.
• The grants include both restricted stock units and stock options, providing a mix of immediate and long-term incentives.
• The use of a Rule 10b5-1(c) plan indicates a pre-arranged transaction, reducing concerns about opportunistic insider trading.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity grants to directors are a standard practice in the biotechnology and pharmaceutical industries, aiming to align leadership incentives with long-term shareholder value creation. The specific vesting schedules reflect common strategies for retention and performance motivation within the sector.

Comparison to Industry Standards

• Equity compensation packages for directors in the biotechnology sector, such as those at Moderna or BioNTech, often include a mix of restricted stock units and stock options, similar to this grant.
• The vesting periods, ranging from short-term (months) to multi-year (3 years), are consistent with industry benchmarks designed to incentivize sustained performance and retention.
• For instance, a typical director compensation package might involve annual RSU grants vesting over 1-3 years and options vesting over 3-4 years, aligning with the long development cycles inherent in drug discovery.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the long-term performance of the company, potentially fostering decisions that enhance shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• Vesting of 1,000 restricted stock units on June 2, 2026.
• Vesting of 2,333 restricted stock units on January 2, 2027.
• Commencement of 36 equal monthly vesting installments for 3,475 stock options starting April 24, 2026.
• Commencement of 10 equal monthly vesting installments for 2,896 stock options starting April 2, 2026.
• Commencement of three equal annual vesting installments for 4,000 restricted stock units starting March 24, 2027.

Key Dates

Keywords

PTC Therapeutics, PTCT, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation, Rule 10b5-1